Kiniksa Pharmaceuticals (NASDAQ:KNSA) Price Target Raised to $30.00 at Evercore ISI

Kiniksa Pharmaceuticals (NASDAQ:KNSA) had its price objective raised by Evercore ISI from $25.00 to $30.00 in a report released on Wednesday, Benzinga reports. Evercore ISI currently has an outperform rating on the stock.

Several other equities research analysts have also recently commented on the stock. Wedbush reissued an outperform rating and set a $30.00 price target on shares of Kiniksa Pharmaceuticals in a research report on Tuesday. TheStreet upgraded Kiniksa Pharmaceuticals from a d+ rating to a c rating in a report on Thursday, February 29th.

Kiniksa Pharmaceuticals Trading Up 1.5 %

KNSA stock opened at $17.88 on Wednesday. The stock has a market cap of $1.26 billion, a PE ratio of 162.56, a price-to-earnings-growth ratio of 5.59 and a beta of 0.27. The stock has a 50-day moving average price of $19.27 and a two-hundred day moving average price of $18.00. Kiniksa Pharmaceuticals has a 1 year low of $10.65 and a 1 year high of $22.09.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its quarterly earnings results on Tuesday, April 23rd. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.11). The business had revenue of $79.90 million for the quarter, compared to the consensus estimate of $76.97 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.32% and a net margin of 2.78%. Kiniksa Pharmaceuticals’s revenue was up 65.4% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.18) earnings per share. On average, analysts forecast that Kiniksa Pharmaceuticals will post -0.04 earnings per share for the current fiscal year.

Insider Activity

In related news, CAO Michael R. Megna sold 9,659 shares of Kiniksa Pharmaceuticals stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $21.45, for a total transaction of $207,185.55. Following the completion of the transaction, the chief accounting officer now owns 17,588 shares in the company, valued at $377,262.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CAO Michael R. Megna sold 9,659 shares of the stock in a transaction on Friday, March 1st. The stock was sold at an average price of $21.45, for a total value of $207,185.55. Following the sale, the chief accounting officer now owns 17,588 shares in the company, valued at approximately $377,262.60. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Sanj K. Patel sold 12,742 shares of Kiniksa Pharmaceuticals stock in a transaction on Monday, March 4th. The stock was sold at an average price of $21.49, for a total transaction of $273,825.58. Following the transaction, the chief executive officer now directly owns 70,594 shares of the company’s stock, valued at $1,517,065.06. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 33,109 shares of company stock valued at $709,929. 54.23% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Tejara Capital Ltd lifted its position in Kiniksa Pharmaceuticals by 3.2% during the third quarter. Tejara Capital Ltd now owns 35,000 shares of the company’s stock worth $608,000 after acquiring an additional 1,069 shares during the last quarter. Los Angeles Capital Management LLC grew its holdings in Kiniksa Pharmaceuticals by 1.1% in the 4th quarter. Los Angeles Capital Management LLC now owns 147,182 shares of the company’s stock valued at $2,582,000 after buying an additional 1,540 shares in the last quarter. QRG Capital Management Inc. increased its position in Kiniksa Pharmaceuticals by 11.7% during the 4th quarter. QRG Capital Management Inc. now owns 16,010 shares of the company’s stock worth $281,000 after buying an additional 1,679 shares during the period. Profund Advisors LLC boosted its position in shares of Kiniksa Pharmaceuticals by 7.8% in the third quarter. Profund Advisors LLC now owns 23,506 shares of the company’s stock valued at $408,000 after acquiring an additional 1,700 shares during the period. Finally, Deutsche Bank AG boosted its position in shares of Kiniksa Pharmaceuticals by 2.5% in the third quarter. Deutsche Bank AG now owns 91,726 shares of the company’s stock valued at $1,593,000 after acquiring an additional 2,220 shares during the period. Institutional investors and hedge funds own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.